Voquezna Dual Pak Kit fda label ndc81520250 is a prescription medication system designed for managing opioid dependence through a structured, clinician-supervised treatment pathway.
This kit combines film formulation and medical oversight tools to support patients in reducing withdrawal symptoms and maintaining stability.
| Regulatory Identifier | Dosage Form | Primary Active Ingredient | Therapeutic Purpose |
|---|---|---|---|
| NDC 81520-250-01 | Film Dispenser | Buprenorphine/Naloxone | Opioid Dependence Maintenance |
| FDA Verified Kit | Unit Dose Packaging | Fixed Ratio Combination | Harm Reduction & Retention |
Understanding Voquezna Dual Pak Kit Components
The Voquezna Dual Pak Kit integrates a film-based delivery system with naloxone safety features to discourage misuse and support adherence.
Each component is selected to meet fda standards for stability, accuracy dosing and patient compliance in medication assisted treatment.
How This Kit Supports Medication Assisted Treatment
Medication assisted treatment protocols rely on consistent dosing, and the dual pak configuration helps align with clinical guidelines for induction and maintenance phases.
Health care professionals can use the kit to monitor progress, adjust counseling strategies, and reinforce behavioral interventions alongside pharmacotherapy.
Key Safety and Handling Features
Specific handling instructions protect the integrity of the film formulation while naloxone additives provide an extra layer of safety against injection misuse.
Patients and providers should follow storage recommendations and disposal guidance to maintain compliance with regulatory standards.
Clinical Considerations and Patient Selection
Clinicians assess liver function, concurrent medications, and history of opioid use to determine if voquezna dual pak kit fda label ndc81520250 is appropriate.
This selection process includes evaluating readiness for treatment, potential drug interactions, and support systems that promote long term recovery.
Practical Recommendations for Users
- Follow the exact dosing schedule prescribed by your clinician without self adjusting.
- Store the kit at controlled room temperature in a secure location away from children.
- Attend all scheduled counseling and medical appointments to support treatment goals.
- Report any side effects or concerns to your healthcare provider promptly.
- Use additional support services, such as peer programs, to reinforce recovery progress.
FAQ
Reader questions
Can this kit be prescribed through telehealth services?
Yes, many clinicians can issue a prescription for voquezna dual pak kit fda label ndc81520250 via telehealth in jurisdictions where regulations allow, often including an initial assessment and ongoing follow up visits.
What should I do if I miss a dose of the film formulation?
Take the missed dose as soon as you remember on the same day, unless it is nearly time for your next scheduled dose, and never double up to compensate for a skipped administration.
Are there specific labs required during treatment with this kit?
Routine monitoring is typically recommended, including assessments of opioid withdrawal signs, adherence confirmation, and evaluation for potential drug interactions rather than mandatory specialty laboratory tests.
How long is the typical treatment duration for this medication system?
Treatment duration varies by individual plan, but many patients use voquezna dual pak kit fda label ndc81520250 for months to years as part of a long term recovery strategy under medical supervision.